Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsRaw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tg Therapeutics (TGTX) Total Liabilities: 2016-2024

Historic Total Liabilities for Tg Therapeutics (TGTX) over the last 9 years, with Dec 2024 value amounting to $355.3 million.

  • Tg Therapeutics' Total Liabilities rose 6.08% to $417.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $417.8 million, marking a year-over-year increase of 6.08%. This contributed to the annual value of $355.3 million for FY2024, which is 110.15% up from last year.
  • According to the latest figures from FY2024, Tg Therapeutics' Total Liabilities is $355.3 million, which was up 110.15% from $169.1 million recorded in FY2023.
  • Tg Therapeutics' Total Liabilities' 5-year high stood at $355.3 million during FY2024, with a 5-year trough of $106.3 million in FY2020.
  • Moreover, its 3-year median value for Total Liabilities was $169.1 million (2023), whereas its average is $219.8 million.
  • As far as peak fluctuations go, Tg Therapeutics' Total Liabilities fell by 14.56% in 2020, and later surged by 110.15% in 2024.
  • Yearly analysis of 5 years shows Tg Therapeutics' Total Liabilities stood at $106.3 million in 2020, then soared by 34.04% to $142.5 million in 2021, then fell by 5.26% to $135.0 million in 2022, then rose by 25.26% to $169.1 million in 2023, then surged by 110.15% to $355.3 million in 2024.